SYDNEY, Dec. 13, 2021 /PRNewswire/ -- Kazia Therapeutics
Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug
development company, is pleased to announce the appointment of
Karen Krumeich as Chief Financial
Officer.
In this role, Ms Krumeich will focus on building and maintaining
relationships with US investors, on preparing the company for
future expansion, and on raising the profile of Kazia in global
markets. Ms Krumeich is based in Pennsylvania in the
United States and will formally commence work with Kazia in
January 2022.
Kazia CEO, Dr. James Garner,
commented, "It is a great pleasure to welcome Karen to Kazia. This
has been a transformative period for the company, and we anticipate
an exciting few years ahead. To that end, we have been taking steps
to augment the company's senior leadership. Karen brings to Kazia
more than thirty years of experience in corporate finance, focused
almost entirely on the life sciences sector, and has driven the
growth of numerous private and public biotech companies."
Ms Krumeich's early career included roles with Grancare, Inc, an
integrated healthcare services provider, and with Bristol-Myers
Squibb, in a senior position with the company's global Health
Systems Management team. For most of the last twenty years, she has
served as Chief Financial Officer to growth-stage biotech
companies, both public and private, including Soligenix, Inc, and,
most recently, Theravectys, Inc. In addition to her accounting
qualifications, Ms Krumeich is a qualified pharmacist.
Ms Krumeich commented, "My excitement with Kazia is driven by
the quality of its pipeline, which includes two very promising
assets. This is an important time for the company, as it matures
from a development-stage venture with a single program to a
pre-commercial company with a richly diversified pipeline. I look
forward to working with the team to help drive the next stage of
the company's growth."
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K / Akt / mTOR pathway, which is being developed to treat
glioblastoma, the most common and most aggressive form of primary
brain cancer in adults. Licensed from Genentech in late 2016,
paxalisib commenced recruitment to GBM AGILE, a pivotal study in
glioblastoma, in January 2021. Eight
additional studies are active in various forms of brain cancer.
Paxalisib was granted Orphan Drug Designation for glioblastoma by
the US FDA in February 2018, and Fast
Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted
Rare Pediatric Disease Designation and Orphan Designation by the US
FDA for DIPG in August 2020.
Kazia is also developing EVT801, a small-molecule inhibitor of
VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided
compelling evidence of synergy with immuno-oncology agents. A phase
I study commenced recruitment in November
2021.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
This document was authorized for release to the ASX by
James Garner, Chief Executive
Officer, Managing Director.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-therapeutics-appoints-karen-krumeich-as-chief-financial-officer-301442797.html
SOURCE Kazia Therapeutics Limited